Phase 4Recruiting

QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic Nephropathy

QUAdruple Therapy With RASi, Empagliflozin, Finerenone, and Mazdutide in Type 2 Diabetes and Early Treatment of Nephropathy(QUARTET-DKD)

Sponsor
Huijie Zhang (Academic or other)
Enrollment
820 planned
Conditions
Type 2 Diabetic Kidney Disease
Interventions
empagliflozin; Finerenone; Mazdutide; Finerenone Placebo; Mazdutide Placebo; Angiotensin Receptor Blocker (ARB)
Ages
adults, older adults
Registry
NCT07775846

Full record on ClinicalTrials.gov

From the registry

This study employs a prospective, randomized, double-blind, parallel-controlled design, aiming to enroll adult participants with type 2 diabetic kidney disease (DKD) who meet the eligibility criteria. With an angiotensin receptor blocker (ARB) as the background therapy, all participants will be randomized in a 1:1:1:1 ratio into four treatment groups: Group 1 (G1): ARB + empagliflozin + finerenone placebo + mazdutide placebo; Group 2 (G2): ARB + empagliflozin + finerenone + mazdutide placebo; Group 3 (G3): ARB + empagliflozin + mazdutide + finerenone placebo; Group 4 (G4): ARB + empagliflozin + mazdutide + finerenone. The primary comparisons include G2 vs. G1, G3 vs. G1, G4 vs. G2, and G4 vs. G3, designed to evaluate the superiority of triple therapy over dual therapy, and quadruple therapy over triple therapy, in reducing the urine albumin-to-creatinine ratio (UACR).

Primary outcomes

  • Relative Change From Baseline in Urine Albumin-to-Creatinine Ratio (UACR) at Month 6

History

  1. Study completion expected

  2. Primary completion expected

  3. Last registry update

  4. Started

  5. Registered